TRDA
Entrada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.82
+10.30%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 7.57x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.80x
- Price / sales
- 40.05x
- Price / cash flow
- -1.39x
Enterprise value
- Enterprise value
- $13.2M
- EV / sales
- 2.82x
- EV / EBITDA
- -0.08x
- EV / EBIT
- -0.07x
- Market cap
- $187.7M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026